Volitionrx Stock EBITDA

VNRX Stock

USD 0.69 0.01 1.43%

Volitionrx fundamentals help investors to digest information that contributes to Volitionrx's financial success or failures. It also enables traders to predict the movement of Volitionrx Stock. The fundamental analysis module provides a way to measure Volitionrx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Volitionrx stock.

		Last Reported	Projected for Next Year
	EBITDA	-34 M	-32.3 M

EBITDA is likely to rise to about (32.3 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Volitionrx Company EBITDA Analysis

Volitionrx's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Volitionrx EBITDA

(34.04 M)

Most of Volitionrx's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Volitionrx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Volitionrx EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Volitionrx is extremely important. It helps to project a fair market value of Volitionrx Stock properly, considering its historical fundamentals such as EBITDA. Since Volitionrx's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Volitionrx's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Volitionrx's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Intangible Assets	Property Plant Equipment	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Capital Surpluse	Short Long Term Debt	Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Net Receivables
Total Assets		0.3	-0.94	-0.85	0.64	0.68	0.99	0.88	-0.89	0.92	0.81	0.44	0.51	0.9	-0.61	0.81	0.86	-0.17	-0.27	0.67	0.52
Total Stockholder Equity	0.3		-0.51	0.19	-0.48	-0.49	0.36	-0.17	-0.11	0.03	-0.2	0.99	-0.65	-0.07	-0.65	-0.02	0.24	0.8	0.77	-0.38	-0.62
Net Debt	-0.94	-0.51		0.65	-0.4	-0.47	-0.97	-0.69	0.77	-0.74	-0.58	-0.64	-0.31	-0.72	0.72	-0.63	-0.73	-0.01	0.07	-0.48	-0.34
Retained Earnings	-0.85	0.19	0.65		-0.92	-0.92	-0.8	-0.99	0.89	-0.96	-0.99	0.05	-0.79	-0.99	0.25	-0.92	-0.82	0.51	0.62	-0.91	-0.77
Accounts Payable	0.64	-0.48	-0.4	-0.92		0.95	0.57	0.91	-0.74	0.81	0.91	-0.37	0.89	0.88	0.0	0.77	0.58	-0.7	-0.79	0.9	0.85
Total Liab	0.68	-0.49	-0.47	-0.92	0.95		0.63	0.93	-0.72	0.81	0.89	-0.35	0.97	0.87	-0.06	0.76	0.6	-0.77	-0.84	0.9	0.96
Total Current Assets	0.99	0.36	-0.97	-0.8	0.57	0.63		0.83	-0.86	0.87	0.75	0.5	0.47	0.85	-0.65	0.76	0.83	-0.13	-0.22	0.62	0.49
Common Stock	0.88	-0.17	-0.69	-0.99	0.91	0.93	0.83		-0.89	0.95	0.96	-0.03	0.81	0.98	-0.3	0.89	0.81	-0.51	-0.62	0.88	0.81
Intangible Assets	-0.89	-0.11	0.77	0.89	-0.74	-0.72	-0.86	-0.89		-0.91	-0.86	-0.24	-0.56	-0.9	0.55	-0.84	-0.85	0.29	0.39	-0.7	-0.55
Property Plant Equipment	0.92	0.03	-0.74	-0.96	0.81	0.81	0.87	0.95	-0.91		0.95	0.17	0.65	0.98	-0.4	0.93	0.9	-0.33	-0.44	0.8	0.64
Short Term Debt	0.81	-0.2	-0.58	-0.99	0.91	0.89	0.75	0.96	-0.86	0.95		-0.07	0.75	0.98	-0.19	0.93	0.83	-0.47	-0.58	0.87	0.73
Net Tangible Assets	0.44	0.99	-0.64	0.05	-0.37	-0.35	0.5	-0.03	-0.24	0.17	-0.07		-0.52	0.07	-0.71	0.09	0.35	0.72	0.69	-0.26	-0.48
Current Deferred Revenue	0.51	-0.65	-0.31	-0.79	0.89	0.97	0.47	0.81	-0.56	0.65	0.75	-0.52		0.72	0.05	0.59	0.41	-0.88	-0.93	0.84	0.99
Capital Surpluse	0.9	-0.07	-0.72	-0.99	0.88	0.87	0.85	0.98	-0.9	0.98	0.98	0.07	0.72		-0.33	0.92	0.85	-0.41	-0.52	0.86	0.71
Short Long Term Debt	-0.61	-0.65	0.72	0.25	0.0	-0.06	-0.65	-0.3	0.55	-0.4	-0.19	-0.71	0.05	-0.33		-0.25	-0.49	-0.16	-0.14	0.03	0.04
Long Term Debt	0.81	-0.02	-0.63	-0.92	0.77	0.76	0.76	0.89	-0.84	0.93	0.93	0.09	0.59	0.92	-0.25		0.93	-0.29	-0.4	0.84	0.58
Long Term Debt Total	0.86	0.24	-0.73	-0.82	0.58	0.6	0.83	0.81	-0.85	0.9	0.83	0.35	0.41	0.85	-0.49	0.93		-0.11	-0.2	0.63	0.4
Net Invested Capital	-0.17	0.8	-0.01	0.51	-0.7	-0.77	-0.13	-0.51	0.29	-0.33	-0.47	0.72	-0.88	-0.41	-0.16	-0.29	-0.11		0.99	-0.6	-0.85
Net Working Capital	-0.27	0.77	0.07	0.62	-0.79	-0.84	-0.22	-0.62	0.39	-0.44	-0.58	0.69	-0.93	-0.52	-0.14	-0.4	-0.2	0.99		-0.7	-0.89
Capital Stock	0.67	-0.38	-0.48	-0.91	0.9	0.9	0.62	0.88	-0.7	0.8	0.87	-0.26	0.84	0.86	0.03	0.84	0.63	-0.6	-0.7		0.83
Net Receivables	0.52	-0.62	-0.34	-0.77	0.85	0.96	0.49	0.81	-0.55	0.64	0.73	-0.48	0.99	0.71	0.04	0.58	0.4	-0.85	-0.89	0.83

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Volitionrx

Ebitda Over Time

Volitionrx Ebitda

Ebitda

(32.34 Million)

Volitionrx reported EBITDA of (34.04 Million) in 2023

According to the company disclosure, Volitionrx reported earnings before interest,tax, depreciation and amortization of (34.04 Million). This is 103.88% lower than that of the Health Care Equipment & Supplies sector and 109.81% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.87% higher than that of the company.

Volitionrx EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Volitionrx's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Volitionrx could also be used in its relative valuation, which is a method of valuing Volitionrx by comparing valuation metrics of similar companies.

Volitionrx is currently under evaluation in ebitda category among its peers.

Volitionrx Current Valuation Drivers

We derive many important indicators used in calculating different scores of Volitionrx from analyzing Volitionrx's financial statements. These drivers represent accounts that assess Volitionrx's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Volitionrx's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	185.7M	176.1M	165.3M	134.5M	51.1M	75.8M
Enterprise Value	172.7M	161.1M	148.8M	128.6M	36.2M	68.4M

Volitionrx Fundamentals

	Return On Equity	-7.3
	Return On Asset	-1.01
	Operating Margin	(17.66) %
	Current Valuation	74.04 M
	Shares Outstanding	92.66 M
	Shares Owned By Insiders	22.80 %
	Shares Owned By Institutions	19.10 %
	Number Of Shares Shorted	441.92 K
	Price To Earning	(4.52) X
	Price To Book	38.44 X
	Price To Sales	66.79 X
	Revenue	775.3 K
	Gross Profit	306.39 K
	EBITDA	(34.04 M)
	Net Income	(35.32 M)
	Cash And Equivalents	16.42 M
	Cash Per Share	0.28 X
	Total Debt	5.86 M
	Debt To Equity	1.57 %
	Current Ratio	1.04 X
	Book Value Per Share	(0.1) X
	Cash Flow From Operations	(18.06 M)
	Short Ratio	3.71 X
	Earnings Per Share	(0.36) X
	Target Price	3.28
	Number Of Employees	101
	Beta	1.1
	Market Capitalization	65.22 M
	Total Asset	27.95 M
	Retained Earnings	(202.58 M)
	Working Capital	(9.98 M)
	Current Asset	6.22 M
	Current Liabilities	1.12 M
	Net Asset	27.95 M

About Volitionrx Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Volitionrx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Volitionrx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Volitionrx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Volitionrx Stock Analysis

When running Volitionrx's price analysis, check to measure Volitionrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Volitionrx is operating at the current time. Most of Volitionrx's value examination focuses on studying past and present price action to predict the probability of Volitionrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Volitionrx's price. Additionally, you may evaluate how the addition of Volitionrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC